A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Clinical trial NCT04224272 · COMPLETED

Trial details

NCT number: NCT04224272
Sponsor: Jazz Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

HER2+/HR+ Breast Cancer

Start date: 2020-06-10
Primary completion: 2023-04-28
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.